Clinical Scorecard: Endogenous Retroviral Elements and Their Influence on Immune Checkpoint Inhibitor Efficacy: Mechanisms, Clinical Insights, and Treatment Considerations
At a Glance
Category
Detail
Condition
Cancer
Key Mechanisms
Reactivation of endogenous retroviruses (ERVs) leads to immune responses via dsRNA detection, enhancing antigen processing and T cell activation.
Target Population
Cancer patients undergoing treatment with immune checkpoint inhibitors (ICIs).
Care Setting
Oncology clinics and research settings.
Key Highlights
ERV signatures may serve as biomarkers for ICI response, independent of PD-L1 or tumor mutational burden.
Therapeutic strategies targeting ERVs can sensitize tumors to ICIs.
Aberrant reactivation of ERVs can trigger immune responses and remodel the tumor immune microenvironment.
Guideline-Based Recommendations
Diagnosis
Assess ERV expression levels as potential biomarkers for ICI efficacy.
Management
Consider therapies that induce ERVs or target ERV antigens to enhance ICI response.
Monitoring & Follow-up
Standardize assays for ERV detection and monitor patient responses to ICI therapy.
Risks
Long-term safety of ERV-targeting therapies remains to be established.
Patient & Prescribing Data
Patients with various cancers receiving ICIs.
Incorporating ERV status into treatment planning may improve outcomes.
Clinical Best Practices
Utilize ERV signatures for patient stratification in ICI therapy.
Monitor immune responses and tumor microenvironment changes during treatment.
